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background. Clostridium difficile infection (CDI) has been extensively described in healthcare settings; however, risk factors associated with
community-acquired (CA) CDI remain uncertain. This study aimed to synthesize the current evidence for an association between commonly
prescribed medications and comorbidities with CA-CDI.
methods. A systematic search was conducted in 5 electronic databases for epidemiologic studies that examined the association between the
presence of comorbidities and exposure to medications with the risk of CA-CDI. Pooled odds ratios were estimated using 3 meta-analytic
methods. Subgroup analyses by location of studies and by life stages were conducted.
results. Twelve publications (n= 56,776 patients) met inclusion criteria. Antimicrobial (odds ratio, 6.18; 95% CI, 3.80–10.04) and
corticosteroid (1.81; 1.15–2.84) exposure were associated with increased risk of CA-CDI. Among the comorbidities, inflammatory bowel
disease (odds ratio, 3.72; 95% CI, 1.52–9.12), renal failure (2.64; 1.23–5.68), hematologic cancer (1.75; 1.02–5.68), and diabetes mellitus (1.15;
1.05–1.27) were associated with CA-CDI. By location, antimicrobial exposure was associated with a higher risk of CA-CDI in the United States,
whereas proton-pump inhibitor exposure was associated with a higher risk in Europe. By life stages, the risk of CA-CDI associated with
antimicrobial exposure greatly increased in adults older than 65 years.
conclusions. Antimicrobial exposure was the strongest risk factor associated with CA-CDI. Further studies are required to investigate the
risk of CA-CDI associated with medications commonly prescribed in the community. Patients with diarrhea who have inflammatory bowel
disease, renal failure, hematologic cancer, or diabetes are appropriate populations for interventional studies of screening.
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introduction
Although the previous literature has focused largely on healthcare-
associated (HA) Clostridium difficile infection (CDI), the inci-
dence, prevalence, and severity of community-acquired (CA) CDI
has also increased.1 Kuntz et al2 reported similar incidence rates
for CA-CDI (11.2 cases/100,000 person-years) and HA-CDI (12.1
cases/100,000 person-years) in the United States. Moreover, the
emergence of “hypervirulent” strains of C. difficile in the com-
munity among patients previously considered to be at low risk of
CDI (ie, young adults without antimicrobial exposure) clearly
shows that the epidemiology of CDI is changing and that CDI is
no longer exclusively a nosocomial infection, as it was previously
considered.1 It seems that the risk profile of patients from the
community points more to increased numbers of younger
patients without comorbidities, whereas in the hospital setting,
elderly inpatients with multiple morbidities and exposed to
polypharmacy remain most at risk.
Research, including through meta-analysis, has attempted to
describe the risk of CDI specifically in the community setting
and found that clindamycin, fluoroquinolones, cephalosporins,
macrolides, penicillins, and sulphonamides/trimethoprim are
associated with an increased CA-CDI risk.3,4 The evidence,
however, remains uncertain because these meta-analyses used
the random effects (RE) model, which has been questioned for
its overconfident results.5 Exposure to gastric-acid suppressive
drugs6–11 and the presence of comorbidities12–14 are associated
with an increased risk of HA-CDI; but as with antimicrobials, the
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evidence remains inconclusive in the community setting. There-
fore, the current meta-analysis was undertaken to pool the
evidence from observational studies so that the magnitude and
direction of the association between commonly prescribed medi-
cations and comorbidities with CA-CDI can be documented.
methods
Search Methodology
A systematic search was undertaken in 5medical and life sciences
databases (PubMed, Embase, Cochrane CENTRAL, Cumulative
Index to Nursing and Allied Health Literature [CINAHL], and
Scopus) from their inception to March 1, 2014 (Appendix 1).
A related citation search was also performed; by combining the
systematic search with the first 20 studies from the related cita-
tion search of selected articles in PubMed, a comprehensive
evaluation of the published evidence can be achieved.15
Eligibility Criteria
The inclusion of studies was restricted to human studies, full-
text articles written in English, studies reporting CA-CDI,
and data presented in an extractable format. Conference
presentations and abstracts, studies that exclusively compared
CA-CDI with HA-CDI, and studies that presented data in a
nonextractable format (ie, graphical representations) were
excluded. Exclusions were also made for studies that investi-
gated specific groups (ie, patients with human immunodefi-
ciency virus or cirrhosis) because these were not considered
representative of the general population.
Study Selection and Data Extraction
Two authors (L.F.-K. and J.C.S.) independently evaluated all
the citations by titles and abstracts for studies that met the
eligibility criteria. Full-text version articles of all potentially
relevant studies were retrieved and independently assessed for
eligibility. Data from the included studies were then indepen-
dently extracted using a predefined tool (Appendix 2) and
summarized in a spreadsheet by the same 2 authors. Extracted
data were cross-checked by the 2 authors, and discrepancies
during the selection of studies or data extraction were resolved
through discussion and consensus following independent
evaluation by another author (S.A.R.D.).
Quality Assessment
The quality of each study was assessed using a modified version
of the Newcastle-Ottawa quality assessment scale for case-
control studies. The modified scale assessed whether 7 safe-
guards against bias had been undertaken by the authors: (1)
definition of cases and methods employed for C. difficile diag-
nosis, (2) selection of CA infection, (3) control definition and
the method used to rule out C. difficile, (4) selection of controls
from the community, (5) analysis adjusted for confounders,
(6) method used for ascertainment of exposure, and (7) same
method used to ascertain exposure for cases and controls. The
quality criteria were combined into a univariate score as outlined
in Table 1. The quality score was rescaled between zero and 1
(called Qi); this was done by summing the points of each com-
ponent (maximum sum= 17) and dividing it by the highest sum
obtained by a study within the meta-analysis, ensuring that the
best quality study always had a Qi of 1.
Statistical Analyses
The outcomemeasure was the odds ratio (OR) for the association
of CA-CDI with exposure to risk factors, such as antimicrobial
drugs, gastric acid suppressant drugs (proton-pump inhibitors
[PPI] and histamine-2-receptor antagonists), nonsteroidal anti-
inflammatory drugs, aspirin, steroids, and the presence of
comorbidities. The OR was pooled using 3 meta-analytic models.
This was justified because some have expressed skepticism
regarding the appropriateness of the conventional RE model16
owing to its documented underestimation of the statistical error,
which leads to overconfident results.5,17–19 The other 2 models
that were used were the quality effects (QE) model 20–21 and a
novel method, the inverse variance heterogeneity (IVhet)
model.22 The QE model uses the Qi to redistribute the inverse
variance weights in favor of the studies with higher methodologic
quality and thus studies that provided higher quality of evidence
contributed with a higher weighting towards the overall effect
size.21 This use of quality information via a univariate score does
not imply that quality deficiencies can quantify bias. Rather, the
quality score is used to rank studies by methodologic rigor and
this rank is then linked with a synthetic bias variance that is added
to the random error variance.20 The other model used was the
IVhet model that does not require input of quality information
and so is less rigorous than the QE model.22 Both of the
latter models use a quasi-likelihood-based variance structure
without distributional assumptions and thus have coverage
probabilities for the confidence interval (CI) well above the
nominal level.22 The reported results are based on the IV
het model; results using the QE and RE models have been
presented for comparative purposes.
Statistically significant heterogeneity was defined as tau-
squared statistic (τ2)> 0, Cochran's Q test P< .1, or I2 index
>0%. A sensitivity analysis was conducted to determine the
degree to which the findings vary depending on the geographic
location where the studies were conducted (America or
Europe) and life stages of the participants (children aged
<2 years, children and adults, adults, or adults aged>65 years).
The Doi plots were used to evaluate the presence of
publication bias, which plots the lnOR against the absolute value
of the z-score for each study.23 Funnel plots were not reported
because the graphical assessment of publication bias requires at
least 10 studies and even then can be difficult to interpret.24
The results of the analyses were considered statistically sig-
nificant if the 95% CI did not include zero. Analyses were
conducted using MetaXL, version 2.0 (EpiGear International).
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table 1. Modified Newcastle-Ottawa Quality Assessment Scale for Case-Control Studies Included in the Meta-analysis
Author, publication
year
Definition
of casesa
Case selection for
community-
acquired infectionb
Definition of
controlsc
Control
selectiond
Analysis adjusted for
confounderse
Ascertainment of
exposuref
Method of
ascertainment of exposure
for cases and controlsg
Total score
(points)
Qi (total
score/13)
Dial et al 200525 1 1 1 2 2 3 1 11 0.85
Dial et al 200627 0 1 0 2 2 3 1 9 0.69
Dial et al 200846 1 1 1 1 3 3 1 11 0.85
Kuntz et al 20112 1 2 1 2 3 3 1 13 1.00
Kutty et al 201030 2 2 2 1 1 3 0 11 0.85
Lowe et al 200632 1 2 0 1 2 3 1 10 0.77
Marwick et al 201331 2 1 0 2 1 3 1 10 0.77
Naggie et al 201147 2 2 2 1 2 1 1 11 0.85
Soes et al 201428 3 2 3 2 0 1 1 12 0.92
Suissa et al 201248 0 1 0 2 2 3 1 9 0.69
Vesteinsdottir et al
201244
2 2 2 2 0 1 1 10 0.77
Wilcox et al 200849 2 0 2 2 0 2 1 9 0.69
aDefinition of cases: Method used for Clostridium difficile diagnosis: stool culture (3 points), toxin detection (2 points), clinical diagnosis or International Classification of Diseases (ICD)
code (1 point), other or no description (0 points).
bCase selection for community-acquired infection: Patient not previously hospitalized and not a resident of a nursing home (2 points), patient not previously hospitalized or not a resident
of a nursing home (1 point), no description (0 points).
cDefinition of controls: Method used for exclusion (noninfection) of C. difficile: stool culture (3 points), toxin detection (2 points), clinical diagnosis or ICD code (1 point), other or no
description (0 points).
dControl selection: Community (2 points), community and hospital (1 point), no description (0 points).
eAnalysis adjusted for exposures other than the primary exposure of interest (sex, age, antimicrobial exposure, gastric acid–suppressive medication exposure or presence of comor-
bidities). Adjusted for 5 factors (3 points), 3–4 factors (2 points), 1–2 factors (1 point), or nonadjusted (0 points).
fAscertainment of exposure: Objective methods, ie, charts or medical records (3 points), reported by the general practitioner (2 points), self-reported (1 point), no description (0 points).
gMethod of ascertainment of exposure for cases and controls: Same (1 point), different (0 points).
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results
Yield of Search Strategy
The initial search identified 1,663 publications. An additional
124 publications were retrieved throughout the related cita-
tions search. After excluding duplicate citations, 1,481 pub-
lications remained. After screening the publications by title
and abstract, 1,388 were excluded. A full-text review of 93
publications was conducted, and 12 met the eligibility criteria
and were selected for the meta-analysis (Figure 1).
There was overlap in subjects between 2 sets of publications.
Two publications (Dial et al25 and Delaney et al26) used data
from the UK General Practice Research Database between
1994 and 2004 and a positive toxin test result for CDI as case
definition to assess the risk of CA-CDI with antimicrobial
exposure. Although Dial et al27 also used data from the UK
General Practice Research Database, the authors reported that
there was no overlap between this and Dial et al25 because
they used different case definitions for CDI.27 Additionally,
2 publications (Soes et al28 and Soes et al29) reported results
from the same Danish cohort. Therefore, Delaney et al26 and
Soes et al29 were excluded from the analyses.
Characteristics of the Included Studies
Twelve publications were included in the meta-analysis. Two
publications reported results divided into groups. Kutty et al30
presented the results of 2 populations (Veterans Affairs and
Durham County residents), whereas Soes et al28,29 presented
the results divided into 2 age groups (<2 years and ≥2 years).
Among the included studies, 7 were case-control studies and
5 were nested case-control studies. The studies included
covered more than 35 years of research and 56,776 patients in
6 different countries. The age of the participants ranged from
3 months to 101 years. Only one study28,29 used exclusively
positive C. difficile culture in the case definition and another
study31 used a combination of C. difficile culture or toxin test
results in the case definition. All studies evaluated exposure to
medication for at least 6 weeks and presence of comorbidities
for at least 12 weeks prior to the index date, respectively
(Table 2). The quality score of the studies ranged from 9 to 13
of 17 (Table 1).
Quantitative Synthesis
When examining the association between drug exposures and
CA-CDI using the IVhet model, exposure to antimicro-
bials (OR, 6.18; 95% CI, 3.80–10.04) and corticosteroids (1.81;
1.15–2.84) were significantly associated with CA-CDI. Gastric
acid–suppressing drugs were not associated with increased odds
of CA-CDI (both PPIs and histamine-2-receptor antagonists:
OR,1.58; 95% CI, 0.90–2.75; just PPIs: 1.61, 0.90–2.88; just
histamine-2-receptor antagonists:1.24, 0.76–2.01). Statistically
significant associations were found between CA-CDI and
the presence of inflammatory bowel disease (OR, 3.72; 95%
CI, 1.52–9.12), renal failure (2.64, 1.23–5.68), leukemia or
figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart of the literature search conducted on March 1,
2014, for the meta-analysis.
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Naggie et al 201147 Duke University
Medical Center,
Durham Regional
Hospital,
Durham VA
Medical Center,
Salisbury VAMC
and Asheville
VAMC, USA
1 Oct 2006–31 Nov
2007
Case-control ≥18 years old 64 (50–73)/
63 (52–74)c
44/45 Symptom onset in
the
community or
within
72 hours of
admission to a
healthcare
facility.
Not hospitalized
during the 12-
week period
prior to the
index
Diarrhea and a positive
toxin test results for
CDI
Outpatient with
no diagnosis
of CDI
Unmatched
Geographic
location
Gastric acid suppressant,
antimicrobials, NSAID,
aspirin, 90
Comorbidity, 720
66/114
Soes et al
201428,29 b
NR, Denmark 24 Aug 2009–
28 Feb 2011
Nested case-
control
Patients who had fecal
sample submitted by
their GP for
microbiological
testing due to
diarrhea or other
gastrointestinal
symptoms
<2 years: 0.95
(0.30–1.98)/1.06
(0.25–1.98)
≥2 years: 50 (2–94)/
50 (2–90) c
<2 years: 53/55
≥2 years: 25/28
Not hospitalized
during the 12-
week period
prior to the
index or onset
of symptoms
within
48 hours of
admission
Positive C. difficile
culture
Negative C. difficile
culture
Laboratory
location, sex,
age (±2 years
if ≥5years;
± 5 months if
≥6months
and < 4years;
± 6 weeks if
< 6months)
Antimicrobials, 56
Gastric acid suppressant,
NSAID, aspirin, 120
Comorbidity, 120
<2 years: 121/213
≥2 years: 138/242
Suissa et al 201248 GPRD, UK 1 Jan 1994–31 Dec
2005
Case-control ≥2 years registered in a
general practice in
the UK and ≥18
years old
NR/NR NR/NR Not hospitalized
the year prior
to the index
date
First positive toxin test
results for CDI, or
first prescription of
oral vancomycin
No clinical
diagnosis,
positive toxin
test result for
CDI or
prescription of
oral
vancomycin
Practice location,
age (±2 years)
Gastric acid suppressant,
antimicrobials, NSAID,
aspirin, 90
Comorbidity, 720
929/10,242
Vesteinsdottir et al
201244
National University
Hospital of
Iceland, Iceland
1 Jul 2010–30 Jun
2011
Case-control ≥18 years old 65 (56–80)/
65 (55–80)c
42.3/42.3 Not hospitalized
during the 6-
week period
prior to the
index or lived
in a nursing
facility and if
hospitalized,
diagnosed
with CDI
within the
72 hours of
admission
Positive toxin test
results for CDI
Negative toxin test
results for
CDI
Sex, age (±5 years) Gastric acid suppressant,
antimicrobials, 42
Comorbidity, 84
111/222
Wilcox et al 200849 Cornwall and Leeds,
UK
Jan 1999–Dec 1999 Case-control Patients who had fecal
sample submitted by
their GP for
microbiological
testing
78 (4–100)/NRc 44/NR Patients that
attended the
GP
Diarrhea and a positive
toxin test results for
CDI
Negative toxin test
results for
CDI
Sex, age categories Antimicrobials, 180
Comorbidity, NR
40/112
NOTE. CDI, Clostridium difficile infection; GP, general practitioner; GPRD, General Practice Research Database; ICD, International Classification of Disease; index date, the date when the cases were identified; MED-ECHO, provincial hospital discharge summary; NR, not reported; NSAID, nonsteroidal
anti-inflammatory drug; VA, Veterans Affairs.
aPresented in 2 groups: Patients from the VA and Durham County.
bPresented in 2 groups: Patients aged < 2 years and ≥2 years.
cAge, median (range), years.
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lymphoma (1.75, 1.02–3.03), and diabetes mellitus (1.15, 1.05–
1.27) (Table 3).
Visual inspection of the forest plots, Cochran's Q test
(Appendix 3), τ2 (results not shown), and I2 index (Table 3 and
Appendix 3) confirmed heterogeneity across studies, except
for exposure to tetracyclines or aspirin and the presence
of chronic obstructive pulmonary disease, diabetes, or diver-
ticular disease.
Sensitivity Analysis
A sensitivity analysis was possible only for antimicrobial and
PPI exposure because of the small number of studies in the
other categories. When stratifying the studies by geographic
location, the sensitivity analysis showed that antimicrobial
exposure had a greater association with CA-CDI in the United
States (OR, 9.16; 95% CI, 5.47–15.34) compared with Eur-
opean countries (4.54, 2.68–7.70; Appendix 4.1). Conversely,
exposure to PPIs had a stronger association with CA-CDI in
Europe (OR, 2.56; 95% CI, 1.40–4.71) compared with the
United States (1.12, 0.64–1.95; Appendix 4.2).
The subgroup analysis by life stages showed that older
adults (>65 years) had the highest risk (OR, 10.16; 95% CI,
5.56–18.58) of CA-CDI when exposed to antimicrobials, fol-
lowed by children and adults (5.98, 4.67–7.67; Appendix 4.3).
When exposed to PPIs, adults had the highest risk of CA-CDI
(OR, 2.78; 95% CI, 2.02–3.81; Appendix 4.4).
Publication Bias
On visual inspection of the Doi plots, there was gross asym-
metry for some exposures, suggesting publication bias in
relation to cephalosporins, fluoroquinolones, macrolides,
penicillin, presence of congestive heart failure, and presence of
gastroesophageal reflux disease. The bias was toward selective
publication that reportedmedication exposure and presence of
comorbidities as risk factors for CA-CDI (Appendix 3).
discussion
Exposure to antimicrobials remained the strongest risk factor
associated with CA-CDI. No statistical significance was
observed in most analyses by antimicrobial class, likely because
table 3. Pooled Effect Size Using the IVhet Model, QE Model, and the RE Model
Exposure
IVhet model OR
(95% CI)
QE model OR
(95% CI)
RE model OR
(95% CI)
Heterogeneity
I2 index %
Antimicrobials 6.18 (3.80–10.04) 6.11 (3.92–9.55) 5.92 (4.21–8.32) 87.90
Cephalosporins 1.80 (0.38–8.46) 2.09 (0.55–7.98) 3.29 (1.20–9.05) 98.39
Clindamycin 2.32 (0.14–37.99) 3.21 (0.30–34.55) 8.35 (1.54–45.20) 97.73
Fluoroquinolones 1.55 (0.32–7.57) 1.90 (0.51–7.05) 3.59 (1.60–8.06) 96.97
Macrolides 1.26 (0.49–3.24) 1.45 (0.64–3.28) 2.15 (1.11–4.17) 93.38
Penicillins 1.31 (0.57–3.01) 1.54 (0.75–3.16) 2.40 (1.40–4.11) 93.50
Tetracyclines 0.98 (0.68–1.41) 0.98 (0.67–1.41) 0.98 (0.68–1.41)a 0
TMP-SMX 1.26 (0.75–2.12) 1.30 (0.80–2.10) 1.37 (0.87–2.15) 77.37
Gastric acid suppressant 1.58 (0.90–2.75) 1.58 (0.95–2.63) 1.58 (1.06–2.34) 68.89
H2RA 1.24 (0.76–2.01) 1.24 (0.78–1.96) 1.37 (0.96–1.96) 73.95
PPI 1.61 (0.90–2.88) 1.63 (0.95–2.80) 1.68 (1.11–2.55) 92.23
Other medication
Aspirin 0.97 (0.87–1.08) 0.96 (0.85–1.08) 0.97 (0.87–1.08)a 0
NSAIDs 1.14 (0.67–1.93) 1.04 (0.63–1.71) 0.83 (0.56–1.23) 90.42
Corticosteroids 1.81 (1.15–2.84) 1.84 (1.22–2.77) 1.65 (1.14–2.38) 34.79
Comorbidities
Congestive heart disease 0.95 (0.45–2.01) 0.98 (0.46–2.06) 1.40 (0.77–2.54) 68.70
COPD 1.04 (0.93–1.16) 1.04 (0.93–1.16) 1.04 (0.93–1.16)a 0
Diabetes mellitus 1.15 (1.05–1.27) 1.14 (1.04–1.26) 1.15 (1.05–1.27)a 0
Diverticular disease 1.15 (0.98–1.36) 1.15 (0.98–1.35) 1.15 (0.98–1.36)a 0
GERD 1.02 (0.74–1.43) 1.03 (0.74–1.43) 1.07 (0.80–1.44) 45.53
Inflammatory bowel disease 3.72 (1.52–9.12) 4.11 (1.78–9.49) 5.19 (2.49–10.83) 89.39
Leukemia or lymphoma 1.75 (1.02–3.03) 1.74 (1.01–3.01) 1.88 (1.09–3.21) 38.95
Peptic ulcer 0.97 (0.60–1.57) 0.96 (0.59–1.56) 0.94 (0.58–1.51) 14.72
Renal failure 2.64 (1.23–5.68) 2.59 (1.20–5.59) 3.02 (1.66–5.48) 85.96
Solid cancer 1.34 (0.83–2.17) 1.35 (0.84–2.17) 1.51 (1.01–2.27) 81.64
NOTE. COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; H2RA, histamine-2-receptor antagonists; IVhet,
inverse variance heterogeneity; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PPI, proton-pump inhibitors; QE, quality
effects; RE, random-effects; TMP-SMX, trimethoprim-sulfamethoxazole. Boldface type indicates statistically significant ORs.
aNo heterogeneity, pooled estimated report using the inverse variance model.
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the largest study (Lowe et al32) reported ORs close to the null
value. However, point estimates confirmed a trend toward an
association with CA-CDI regardless of antimicrobial class
exposure. These observations corroborated previous findings
published by Deshpande et al3 and Brown et al4 that suggested
an increased risk of CA-CDI as a result of antimicrobial
exposure.
Despite the growing evidence in the past decade with respect
to increased risk of HA-CDI after exposure to PPIs6,7,9–11 or
histamine-2-receptor antagonists,8,25 no significant associa-
tion was observed in the community setting. The observed
difference between the risk of CA-CDI and HA-CDI with
gastric-acid suppressive medication can be explained by the
overuse of these medications in healthcare facilities.33 Exposure
to corticosteroids was associated with CA-CDI. In contrast to
antimicrobials that disrupt the normal gut microbiome, facil-
itating the proliferation of C. difficile,34 and in contrast to gastric-
acid suppressive medication that may allow survival of vegetative
forms of C. difficile,35 a plausible biological mechanism for the
observed association could be the negative impact of corticos-
teroids on the gastrointestinal mucosal integrity.36
Previous studies found that gastrointestinal comorbidities
such as inflammatory bowel disease12 and cirrhosis14 were
associated with a worse prognosis in patients with CDI. Simi-
larly, congestive heart disease, chronic pulmonary disease, renal
failure, and malignant neoplasms were also associated with
higher mortality rates among inpatients with CDI.13 Among the
comorbidities examined in this meta-analysis, inflammatory
bowel disease was the strongest risk factor for CA-CDI, followed
by renal failure and hematologic cancers. In patients with
the described comorbidities, early identification and prompt
treatment of CA-CDI may reduce mortality rates. The associa-
tions found between CA-CDI and comorbidities may be
confounded by medication exposure, given that polypharmacy
is common among patients with multiple comorbidities. Fur-
thermore, the heterogeneous definition of CA-CDI across the
studies (ie, not hospitalized the year prior to the index date
versus not hospitalized 6 weeks prior to the index date) may also
be a source of misclassification between CA- and HA-CDI,
considering that patients with multiple comorbidities are more
likely to be admitted to hospitals.
The sensitivity analyses suggested that risk of CA-CDI with
exposure to antimicrobials and PPI differed between Europe
and America. The observed difference might be due to the
dissimilar prescription of antimicrobials37 and/or the presence
of different strains of C. difficile in Europe and America.38
Similarly, the risk of CA-CDI with exposure to antimicrobials
and PPI varied among the life stages. These findings were
consistent with Sandora et al,39 who reported a negative
correlation between age and CA-CDI among pediatric popu-
lations, and with Lessa et al,40 who reported a higher incidence
of CDI among patients at both extremes of life (1–4 years of
age and older than 65 years). In the past 2 decades, a 12-fold
increased incidence of CA-CDI among the pediatric popula-
tion41 and numerous outbreaks in long-term care facilities42
have been reported, indicating that infants, toddlers, and older
adults should be considered at high risk of CA-CDI.
Although a comprehensive systematic search for studies was
performed, publication bias could have resulted in additional
positive associations being published, such as those between
CA-CDI and exposure to cephalosporins, fluoroquinolones,
macrolides, and penicillins and the presence of congestive heart
disease and gastroesophageal reflux disease. The actual risks
attributable to these risk factors could be less than what we have
reported. Nevertheless, heterogeneity across studies could also
result in effect size asymmetry, and this represents an alternative
explanation to selective publication of positive results.
Recent meta-analyses have investigated the risk of CDI asso-
ciated with exposure to antimicrobials3,4,6 and gastric acid sup-
pressant drugs6–9 using the widely adopted REmodel.16 However,
the coverage probability of the RE CI can be substantially
below the nominal level of 95% and thus does not adequately
reflect the statistical error, especially when there are few included
studies.5,22,43 By underestimating the statistical error, the RE
model produces tight CIs that potentially cause overconfident
results prone to type 1 error. Moreover, the assumption of nor-
mally distributed random effects is not easily verified.43 The use of
a moment-based common variance16 within this model is in the
redistribution of the weights from larger to smaller studies.18 The
QE and IVhet models have both been created to do away with
the problems that affect the RE model and both have coverage of
the CI at or above the nominal level.22 As an example, with the
clindamycin pooled estimates, the IVhet model distributed
the weight (83.5%) toward the biggest study (Lowe et al32;
n= 13,692). The QE model took into account the extra infor-
mation regarding the quality of the studies and penalized the
biggest study by reducing the assigned weight (from 83.5% to
69.0%) because it had the lowest quality score; whereas the RE
model redistributed the weights by equalizing weights (by trans-
ferring from big to small studies) and thus, it gave a weight per-
centage to the biggest study (Lowe et al32; n= 13,692; weight
25.85%) that was similar to that of the smallest study (Vesteins-
dottir et al44; n =333; weight 23.98%). Moreover, the RE model
produced a tighter CI (with a statistically significant result), but its
coverage may have been under the nominal level and thus may
not have captured the true value of the effect (Appendix 3.3).
Several limitations of the present meta-analysis were noted.
Kuntz et al2 and Marwick et al31 reported a positive relation-
ship between duration of exposure to antimicrobials and
CA-CDI. However, the small number of studies precluded a
subgroup analysis by duration of exposure to antimicrobials. All
studies included in this meta-analysis were conducted in
Northern Hemisphere countries. A recent study has described a
different seasonal pattern of CDI in Australia that remains
largely unexplained.45 The epidemiologic patterns of C. difficile
transmission and infectionmay differ between hemispheres and
thus generalizability of the findings to Southern Hemisphere
countries is limited.
In conclusion, while antimicrobial use remains the domi-
nant risk factor for CA-CDI, corticosteroid use should also
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be considered an important risk factor. Given these are com-
monly prescribed medications in the community, the
attributable risk of CDI due to exposure may be high and thus
further research is warranted. In addition, patients with inflam-
matory bowel disease, renal failure, and hematologic cancer are
at higher risk of CA-CDI, making them appropriate populations
for interventional studies of screening for C. difficile.
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